secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2024-04-10T23:59:59+00:00
Accession:  0001787306-24-000046
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis appoints David Topper as CFO, replacing interim CFO John Smither
------------------------------------------------------------------------

- David Topper named CFO effective April 10, 2024; John Smither steps down and resigns April 30.
- Topper receives $515k base salary, 45% target bonus, and equity awards of 310k options, 110k RSUs, 60k PSUs.
- Topper brings 40+ years experience; most recently CFO at Inmagene, ex-General Atlantic, J.P. Morgan, Morgan Stanley.
- Smither served as interim CFO since August 2023; previously Arcutis' first CFO leading IPO.
- Topper's severance agreement includes 12 months base plus bonus, COBRA, and full equity acceleration on qualifying termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730624000046/0001787306-24-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730624000046/arqt-20240410.htm
  HTML page:      https://secwatch.observer/filing/0001787306-24-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer